GHRP-7
GHRP-7 is an obscure modified hexapeptide analog in the growth hormone releasing peptide series with very limited published data, representing one of the less characterized variants from GHS-R1a structure-activity research.
GHRP-7 is a modified hexapeptide analog belonging to the growth hormone releasing peptide family. It represents one of the more obscure variants generated during the extensive structure-activity relationship studies of GHS-R1a receptor ligands.
Overview
The growth hormone releasing peptide series encompasses numerous analogs developed through systematic modification of the hexapeptide scaffold first identified by Cyril Bowers. While GHRP-1, GHRP-2, and GHRP-6 achieved prominence in research and clinical diagnostics, higher-numbered variants like GHRP-7 received considerably less investigation. GHRP-7 is referenced primarily in the context of GHRP family overviews and patent literature rather than in dedicated pharmacological studies. The limited data available does not permit definitive statements about its relative potency, selectivity, or therapeutic potential.
Mechanism of Action
As a GHRP-family hexapeptide, GHRP-7 is presumed to act through the growth hormone secretagogue receptor type 1a (GHS-R1a). This receptor, a G protein-coupled receptor on pituitary somatotrophs, mediates GH release through phospholipase C/calcium signaling when activated by GHRP-class ligands. The mechanism operates independently of the GHRH receptor pathway, which is the basis for the synergistic GH release observed when GHRPs are combined with GHRH analogs. The specific binding characteristics of GHRP-7 at GHS-R1a have not been reported in the published literature.
Reconstitution Calculator
GHRP-7
GHRP-7 is a modified hexapeptide analog belonging to the growth hormone releasin
Set up a clean workspace with all supplies ready.
7x / week for weeks
Research
Very Limited Published Data
GHRP-7 has essentially no dedicated pharmacological characterization in the peer-reviewed literature. Unlike GHRP-2 (which advanced to clinical diagnostic use as pralmorelin) and GHRP-6 (which has been studied in numerous research contexts), GHRP-7 lacks published dose-response data, receptor binding studies, comparative potency assessments, and safety evaluations. This absence of data makes it one of the least characterized members of the GHRP family.
Structure-Activity Context
The GHRP numbering system reflects the order in which analogs were synthesized and screened during the optimization campaign led by Bowers and colleagues. Each variant incorporates specific amino acid substitutions at defined positions within the hexapeptide backbone. GHRP-2 emerged as the most selective analog, while GHRP-6 became the most widely studied for GH provocative testing. Higher-numbered variants such as GHRP-7 were either screened and deprioritized based on inferior pharmacological profiles or represent later modifications that did not demonstrate sufficient advantages to warrant further development (Bowers, 1998).
Broader GHRP Family Pharmacology
For context, the well-characterized GHRPs share several properties: dose-dependent GH release through GHS-R1a agonism, synergistic interaction with GHRH, and varying degrees of cortisol and prolactin elevation depending on the specific analog and dose. The family collectively led to the identification of the GHS-R1a receptor and subsequently to the discovery of ghrelin as its endogenous ligand (Kojima et al., 1999). These shared properties likely apply to GHRP-7 in principle, though specific parameters remain unknown.
Safety Profile
No safety data specific to GHRP-7 have been published. The GHRP hexapeptide family as a class has demonstrated a generally favorable safety profile at standard research doses, with dose-dependent cortisol and prolactin elevation representing the primary hormonal side effects. GHRP-2 has been approved in Japan as a diagnostic agent (pralmorelin provocation test) with established clinical safety data. In the absence of GHRP-7-specific safety evaluation, caution is warranted and extrapolation from other GHRP analogs should be considered preliminary.
Clinical Research Protocols
GHRP-7 has not been evaluated in any clinical trial or standardized research protocol. No entries appear on ClinicalTrials.gov. For researchers interested in GHRP-class pharmacology, established clinical protocols exist for GHRP-2 (pralmorelin provocation test: 1 mcg/kg IV with serial GH sampling) and GHRP-6 (various GH stimulation protocols). These well-validated protocols provide the appropriate framework for studying GH secretagogue effects.
Synergies & Combinations
No combination studies involving GHRP-7 have been published. The synergistic interaction between GHRPs and GHRH is a class-wide property arising from the distinct receptor mechanisms (GHS-R1a vs. GHRH-R). If GHRP-7 acts through GHS-R1a as presumed, it would be expected to synergize with GHRH analogs such as Mod GRF 1-29 and sermorelin. However, this has not been experimentally confirmed.
Pharmacokinetic Profile
GHRP-7 — Pharmacokinetic Curve
Subcutaneous injection, IntravenousQuick Start
- Route
- Subcutaneous injection, Intravenous
Research Protocols
subcutaneous Injection
Administered via subcutaneous injection.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | 1 mcg | Per protocol | — |
intravenous Injection
Administered via intravenous injection.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Researchers interested in GHRP-class phar | 1 mcg | Per protocol | — |
What to Expect
What to Expect
Rapid onset expected; half-life of Not determined (estimated 15-30 minutes based on GHRP class) indicates fast-acting pharmacokinetics
Due to short half-life (Not determined (estimated 15-30 minutes based on GHRP class)), effects are expected per-dose; consistent daily administration...
Regular administration schedule required; effects are dose-dependent and do not persist between doses
Quality Indicators
What to look for
- Well-established safety profile
Frequently Asked Questions
References (5)
- [3]Kojima et al *Nature* Nature (1999)
- [5]
- [6]
- [1]Bowers CY *Cell Mol Life Sci* Cell Mol Life Sci (1998)
- [4]Bowers CY et al *Endocrinology* Endocrinology (1994)
GHRP-6
GHRP-6 is a synthetic ghrelin receptor agonist and growth hormone secretagogue with research applications in neuroprotection, memory, wound healing, cardiac protection, and mood regulation.
GIP (Glucose-Dependent Insulinotropic Polypeptide)
GIP (Glucose-Dependent Insulinotropic Polypeptide) is an endogenous incretin hormone produced by intestinal K-cells that potentiates insulin secretion and plays key roles in lipid metabolism, bone health, and adipose tissue function. It is a critical component of tirzepatide's dual agonist mechanism.